Home » Stocks » T2 Biosystems

T2 Biosystems, Inc. (TTOO)

Stock Price: $2.08 USD 0.38 (22.06%)
Updated Aug 10, 2020 2:52 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 248.04M
Revenue (ttm) 9.10M
Net Income (ttm) -58.81M
Shares Out 119.54M
EPS (ttm) -1.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $2.08
Previous Close $1.70
Change ($) 0.38
Change (%) 22.06%
Day's Open 1.74
Day's Range 1.72 - 2.14
Day's Volume 31,963,301
52-Week Range 0.24 - 3.21

More Stats

Market Cap 248.04M
Enterprise Value 256.29M
Earnings Date (est) Aug 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 119.54M
Float 111.88M
EPS (basic) -1.17
EPS (diluted) -1.14
FCF / Share -0.70
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.95M
Short Ratio 0.65
Short % of Float 10.04%
Beta 1.23
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 27.27
PB Ratio n/a
Revenue 9.10M
Operating Income -52.06M
Net Income -58.81M
Free Cash Flow -47.87M
Net Cash -8.25M
Net Cash / Share -0.07
Gross Margin -272.17%
Operating Margin -572.41%
Profit Margin -646.60%
FCF Margin -526.31%
ROA -60.87%
ROE n/a
ROIC -1,624.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$3.17*
(52.77% upside)
Low
2.00
Current: $2.08
High
4.00
Target: 3.17
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue8.3410.504.674.082.810.120.270.02
Revenue Growth-20.62%125.03%14.36%45.04%2263.87%-55.26%1300%-
Gross Profit-8.43-4.90-7.36-2.791.070.120.270.02
Operating Income-52.06-45.09-53.85-50.88-43.38-30.68-19.69-14.65
Net Income-59.01-51.15-62.43-54.80-45.29-31.39-20.61-14.46
Shares Outstanding45.5140.5632.1326.0220.508.671.401.36
Earnings Per Share-1.30-1.26-1.94-2.11-2.21-4.15-19.72-13.86
Operating Cash Flow-45.36-40.14-47.72-46.44-37.47-28.18-18.05-13.30
Capital Expenditures-0.76-0.59-2.48-5.49-7.97-2.08-0.51-0.28
Free Cash Flow-46.12-40.73-50.19-51.93-45.44-30.27-18.57-13.59
Cash & Equivalents11.2150.9942.0673.7573.9273.9330.209.79
Total Debt44.7842.3741.7040.7730.5720.965.065.88
Net Cash / Debt-33.568.610.3632.9843.3552.9725.143.91
Assets28.4964.3154.8689.5786.8379.1331.8911.43
Liabilities62.4952.9253.5250.2339.8926.1312174.09
Book Value-34.0111.391.3439.3446.9453.00-89.54-62.66
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name T2 Biosystems, Inc.
Country United States
Employees 118
CEO John J. Sperzel

Stock Information

Ticker Symbol TTOO
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: TTOO
IPO Date August 7, 2014

Description

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it is developing Candida Auris, a multi-drug resistant pathogen; T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; and T2Lyme for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC to develop detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate, as well as for testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.